Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

SeaStar Medical Holding (ICU) Research & Development (2023 - 2025)

SeaStar Medical Holding (ICU) has disclosed Research & Development for 3 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development fell 20.8% year-over-year to $1.8 million, compared with a TTM value of $8.1 million through Sep 2025, up 6.82%, and an annual FY2024 reading of $9.1 million, up 52.44% over the prior year.
  • Research & Development was $1.8 million for Q3 2025 at SeaStar Medical Holding, up from $1.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $2.7 million in Q4 2024 and bottomed at $1.0 million in Q2 2025.
  • Average Research & Development over 3 years is $1.9 million, with a median of $1.8 million recorded in 2025.
  • The sharpest move saw Research & Development surged 133.02% in 2024, then plummeted 55.57% in 2025.
  • Year by year, Research & Development stood at $1.2 million in 2023, then soared by 133.02% to $2.7 million in 2024, then tumbled by 32.43% to $1.8 million in 2025.
  • Business Quant data shows Research & Development for ICU at $1.8 million in Q3 2025, $1.0 million in Q2 2025, and $2.4 million in Q1 2025.